164 related articles for article (PubMed ID: 11369844)
1. The CREATE trial--building the evidence.
Eckardt KU;
Nephrol Dial Transplant; 2001; 16 Suppl 2():16-8. PubMed ID: 11369844
[TBL] [Abstract][Full Text] [Related]
2. The beneficial effects of intervention in early renal disease.
Portolés J
Nephrol Dial Transplant; 2001; 16 Suppl 2():12-5. PubMed ID: 11369843
[TBL] [Abstract][Full Text] [Related]
3. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
4. Managing a fateful alliance: anaemia and cardiovascular outcomes.
Eckardt KU
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi16-20. PubMed ID: 15958821
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.
Eckardt KU; Scherhag A; Macdougall IC; Tsakiris D; Clyne N; Locatelli F; Zaug MF; Burger HU; Drueke TB
J Am Soc Nephrol; 2009 Dec; 20(12):2651-60. PubMed ID: 19850955
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular consequences of renal anaemia and erythropoietin therapy.
Eckardt KU
Nephrol Dial Transplant; 1999 May; 14(5):1317-23. PubMed ID: 10344393
[TBL] [Abstract][Full Text] [Related]
7. New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial.
Laville M;
Acta Diabetol; 2004 Mar; 41 Suppl 1():S18-22. PubMed ID: 15103544
[TBL] [Abstract][Full Text] [Related]
8. [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
Jiang JP; Hou FF; Gao LZ; Pan YB; Yang NS; Chen W; Shu GY; Chen YM; Chen J; Peng WH; Wu JP; Yang ZM
Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):25-9. PubMed ID: 15769393
[TBL] [Abstract][Full Text] [Related]
9. What are the short-term and long-term consequences of anaemia in CRF patients?
Mann JF
Nephrol Dial Transplant; 1999; 14 Suppl 2():29-36. PubMed ID: 10334665
[TBL] [Abstract][Full Text] [Related]
10. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
Hampl H; Hennig L; Rosenberger C; Amirkhalily M; Gogoll L; Riedel E; Scherhag A
Am J Nephrol; 2005; 25(3):211-20. PubMed ID: 15900093
[TBL] [Abstract][Full Text] [Related]
11. CREATE: new strategies for early anaemia management in renal insufficiency.
Macdougall IC; ;
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii13-6. PubMed ID: 12819295
[TBL] [Abstract][Full Text] [Related]
12. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
Locatelli F; Aljama P; Canaud B; Covic A; De Francisco A; Macdougall IC; Wiecek A; Vanholder R;
Nephrol Dial Transplant; 2010 Sep; 25(9):2846-50. PubMed ID: 20591813
[TBL] [Abstract][Full Text] [Related]
13. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
Levin A; Djurdjev O; Thompson C; Barrett B; Ethier J; Carlisle E; Barre P; Magner P; Muirhead N; Tobe S; Tam P; Wadgymar JA; Kappel J; Holland D; Pichette V; Shoker A; Soltys G; Verrelli M; Singer J
Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular hypertrophy: why does it happen?
London GM
Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii2-6. PubMed ID: 14607992
[TBL] [Abstract][Full Text] [Related]
15. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
17. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial.
Roger SD; McMahon LP; Clarkson A; Disney A; Harris D; Hawley C; Healy H; Kerr P; Lynn K; Parnham A; Pascoe R; Voss D; Walker R; Levin A
J Am Soc Nephrol; 2004 Jan; 15(1):148-56. PubMed ID: 14694167
[TBL] [Abstract][Full Text] [Related]
18. A need for an individualized approach to end-stage renal disease patients.
Hörl WH
Nephrol Dial Transplant; 2002; 17 Suppl 6():17-21. PubMed ID: 12091597
[TBL] [Abstract][Full Text] [Related]
19. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
Dunn CJ; Markham A
Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of cardiovascular damage in early renal disease.
Levin A
Nephrol Dial Transplant; 2001; 16 Suppl 2():7-11. PubMed ID: 11369842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
